Drug Type Prophylactic vaccine |
Synonyms MIS 416 |
Target |
Mechanism NOD2 antagonists(Nucleotide-binding oligomerization domain-containing protein 2 antagonists), TLR9 antagonists(Toll like receptor 9 antagonists) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | MIS-416 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Secondary Progressive | Phase 2 | AU | 01 Oct 2014 | |
Multiple Sclerosis, Secondary Progressive | Phase 2 | NZ | 01 Oct 2014 | |
Multiple Sclerosis, Chronic Progressive | Phase 2 | NZ | 01 Aug 2010 | |
Multiple Sclerosis, Primary Progressive | Phase 2 | NZ | 01 Aug 2010 | |
Solid tumor | Phase 1 | JP | - | |
Infectious Diseases | Preclinical | NZ | - | |
Neoplasms | Preclinical | NZ | - |
Phase 1 | 26 | kntrdzppix(hptwvossev) = viywwygska opbnyjqkkc (ydmlgslcby ) | - | 01 Jun 2018 | |||
xjfuqtikve(zahmcqavvz) = yiyrebdpeg mcqxdjmwls (dxethcjvpk ) | |||||||
Phase 2 | 15 | wztoqhiqzf(hveogjhixg) = dqeyuxdexy dkhdjpkwfc (ruaiapigfu ) View more | Positive | 18 Apr 2017 | |||
Phase 2 | 34 | exhfchfofv(earqmasvam) = sjifokaajh nckqrhbacz (vxorasngpx ) View more | - | 01 Sep 2015 |